Hilda Leung

Associate

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Hilda Leung is an associate in O’Melveny’s Hong Kong office. She focuses her practice on corporate finance and capital markets. She also advises on regulatory compliance and general corporate matters.

Languages

  • English
  • Cantonese
  • Mandarin

Admissions

  • Hong Kong

Education

  • University of Hong Kong, P.C.LL.; LL.B.; BSocSc
  • OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds
  • Acotec Scientific Holdings Limited in its US$210 million IPO and listing on the Hong Kong Stock Exchange
  • Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited and other underwriters in the US$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
  • China VAST Industrial Urban Development Company Limited and its major shareholder in the sale of approximately US$191 million of shares to China Jinmao Holdings Group Limited, and the issuance of 6% convertible bonds of US$123 million with a 36 month maturity date to China Jinmao
  • CCB International Capital Limited as sole sponsor and other underwriters in the approximately US$85 million IPO and listing of Kangqiao Service Group Limited on the Hong Kong Stock Exchange
  • RemeGen Co., Ltd. in its US$515 million IPO and listing on the Hong Kong Stock Exchange
  • A buyer consortium led by Yunfeng Capital, TF Capital, GIC and management in connection with the acquisition of Cellular Biomedicine Group in a “going private” transaction valued at approximately US$380 million
  • J.P. Morgan, BofA Securities, CICC and Haitong International as joint sponsors and other underwriters in the approximately US$1.67 billion secondary listing of GDS Holdings Limited on the Hong Kong Stock Exchange
  • Yeahka Limited (9923.HK) in its US$212 million IPO on the Hong Kong Stock Exchange
  • Akeso, Inc. (9926.HK) in its US$383 million IPO on the Hong Kong Stock Exchange
  • Pharmaron Beijing Co., Ltd. (300759.SZ and 3759.HK) in its US$588 million dual primary listing and H share offering on the Hong Kong Stock Exchange
  • Shanghai Kindly Medical Instrument Co., Ltd. (1501.HK) in its US$106 million IPO on the Hong Kong Stock Exchange
  • Caitong International Capital Co., Limited as the sponsor in the transfer of listing of China Wan Tong Yuan (Holdings) Limited (6966.HK) from GEM to the Hong Kong Stock Exchange
  • Aesthetic Medical International Holdings Group (Nasdaq: AIH) in its US$34.5 million IPO on the Nasdaq
  • Viva Biotech (1873.HK) in its US$194 million IPO on the Hong Kong Stock Exchange
  • Dexin China Holdings Company Limited (2019.HK) in its US$190 million IPO on the Hong Kong Stock Exchange